Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity (2015 - 2026)

Syndax Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $472.7 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 26.23% year-over-year to $472.7 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 5.2% decrease from a year earlier, with the FY2025 full-year figure at $529.7 million, down 26.92% from the prior year.
• Liabilities and Shareholders Equity fell to $472.7 million in Q1 2026 per SNDX's latest filing, from $529.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $724.8 million in Q4 2024 and bottomed at $359.7 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $476.9 million (2024), against an average of $503.0 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 54.5% in 2022 and dropped 26.92% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $497.2 million in 2022, then rose by 23.26% to $612.9 million in 2023, then gained by 18.26% to $724.8 million in 2024, then fell by 26.92% to $529.7 million in 2025, then decreased by 10.77% to $472.7 million in 2026.
• Per Business Quant, the three latest SNDX Liabilities and Shareholders Equity figures stand at $472.7 million (Q1 2026), $529.7 million (Q4 2025), and $551.8 million (Q3 2025).